Welcome to our dedicated page for Evolus SEC filings (Ticker: EOLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolus, Inc. (EOLS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the details. Evolus is a Nasdaq-listed performance beauty company focused on aesthetic injectables, and its filings provide formal insight into financial performance, governance, and key events affecting its Jeuveau neurotoxin and Evolysse hyaluronic acid (HA) gel portfolio.
Investors can use this page to access current and historical 10-K and 10-Q reports, which describe Evolus’ business, risk factors, and financial statements, including revenue contributions from Jeuveau and Evolysse products and discussion of non-GAAP operating metrics. Form 8-K filings, such as those announcing quarterly results or executive appointments, document material events like financial updates, leadership changes, and significant clinical or commercial milestones.
The page also surfaces Form 4 insider transaction reports, where applicable, which disclose purchases, sales, or grants of Evolus common stock by directors and officers. These filings allow users to track how insiders’ equity holdings change over time in connection with inducement grants, stock option awards, and restricted stock units described in company announcements.
Stock Titan’s AI features summarize lengthy filings into plain-language highlights, explaining how items such as non-GAAP operating income, restructuring costs, or contingent royalty obligations appear in Evolus’ disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks are added as soon as they are filed, while AI-generated overviews help users quickly identify sections related to revenue trends, operating expenses, executive compensation agreements, and governance provisions. This combination of raw documents and AI analysis helps investors, analysts, and other stakeholders understand the regulatory record behind EOLS stock and the company’s performance beauty strategy.
Evolus, Inc. reported Q3 2025 results with total net revenues of $68,967, up from $61,085 a year ago. Gross profit was $45,841, but operating expenses of $57,341 (including $1,443 in restructuring costs) led to a loss from operations of $11,500 and a net loss of $15,737, or $0.24 per share.
Cash and cash equivalents were $43,523 at quarter end, with net cash used in operating activities of $55,092 year-to-date. Long‑term debt on the balance sheet was $145,780, reflecting the May 2025 Amended and Restated Loan Agreement that provides up to $250,000 in senior secured term loans, including an initial $150,000 funded. Stockholders’ equity was a deficit of $28,760. The company launched Evolysse Form and Smooth in the U.S. in April 2025 and continues to commercialize Jeuveau across multiple markets. Shares outstanding were 64,819,784 as of October 31, 2025.
Evolus, Inc. (EOLS) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. As provided in General Instruction B.2, the information in Item 2.02 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act, and will only be incorporated by reference if specifically stated in a future filing.
Evolus, Inc. reported that its Chief Financial Officer was granted both restricted stock units and stock options on 09/08/2025. The CFO received 104,603 RSUs, each convertible into one share on settlement, and a stock option covering 143,403 shares with an exercise price of $7.61 that expires on 09/08/2035. The RSUs vest over four years with one-half vesting on each of the third and fourth anniversaries of the grant date, while the option vests in four annual tranches starting on the first anniversary. Both awards include accelerated vesting in specified termination or change‑of‑control events. Following the grants the reporting person beneficially owns 104,603 shares and has the right to acquire 143,403 additional shares under the option.
Evolus, Inc. reporting person Tatjana Mitchell filed an initial Form 3 reporting her relationship to the company as Chief Financial Officer and a Director. The filing states the event date as 09/08/2025 and explicitly declares that no securities are beneficially owned by the reporting person at the time of the filing. The Form 3 was signed by an attorney‑in‑fact on 10/09/2025. This is a routine Section 16 initial disclosure showing the officer has no reportable ownership in the issuer.
Evolus, Inc. reported a material event on September 8, 2025 via a Current Report on Form 8-K noting two procedural disclosures.
First, the filing references an Employment Agreement described as Exhibit 10.11 to the company's Form S-1 filed January 25, 2018, and states a full copy of that Employment Agreement will be filed as an exhibit to the company's Quarterly Report for the quarter ended September 30, 2025. Second, Evolus furnished a press release as Exhibit 99.1 announcing certain matters described elsewhere in the filing; the exhibit is furnished but not "filed" for Section 18 liability purposes.
The current report contains procedural exhibit references and timing for later exhibit filings but does not include substantive details of the employment terms or the press release text within the body of the filing.
Insider sale under 10b5-1 plan: Tomoko Yamagishi-Dressler, Chief Marketing Officer and director at Evolus, Inc. (EOLS), reported the sale of 5,722 shares of the company's common stock on 08/22/2025 at a price of $7.51 per share. After the transaction, the reporting person beneficially owned 89,949 shares. The filing indicates the sale was made pursuant to a Rule 10b5-1 trading plan and that the shares sold were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units.
Form and signature: The Form 4 was executed by an attorney-in-fact on behalf of the reporting person and includes the standard certification language required by Section 16 filings.
Stewart Brady, a director of Evolus, Inc. (EOLS), purchased 30,000 shares of the issuer's common stock on 08/15/2025 at a weighted average price of $6.8162 per share, increasing his beneficial ownership to 88,629 shares. The Form 4 reports the shares were bought in multiple trades at prices ranging from $6.7699 to $6.82, and the filing was signed by Jeffrey J. Plumer as attorney-in-fact on 08/18/2025. The transaction is reported as a purchase and the ownership is listed as direct.
Timothy P. Lynch reported beneficial ownership of 4,094,489 shares of Evolus, Inc. common stock, representing 6.3% of the class based on 64,685,419 shares outstanding as of August 1, 2025. The filing shows Mr. Lynch holds 3,492,130 shares with sole voting and dispositive power and 602,359 shares with shared voting and dispositive power. The Schedule identifies the issuer's principal executive offices at 520 Newport Center Drive, Newport Beach, California.
The filing is a Schedule 13G and includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer. The reporting person’s address is listed as 70 SW Century Dr, STE 100 PMB 1257, Bend, OR 97702, and the signature is dated 08/15/2025.
Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 2,474,843 shares of Evolus, Inc. common stock, representing 3.8% of the outstanding class based on 64,685,419 shares outstanding as stated in the filing. The holdings are reported as shared voting and shared dispositive power; none of the Reporting Persons claim sole voting or sole dispositive power. The filing states the Master Fund directly holds the shares and Perceptive Advisors acts as its investment manager, with Mr. Edelman as managing member.
Caligan Partners LP and its managing partner David Johnson filed a Schedule 13G reporting shared beneficial ownership of 3,341,970 shares of Evolus, Inc. common stock, representing 5.2% of the class based on 64,475,589 shares outstanding as of May 2, 2025. The reporting persons state the shares are held by Caligan Partners Master Fund LP and a managed account and are owned in the ordinary course of business, not to influence control of the company. Caligan is organized in Delaware and Mr. Johnson is a U.S. citizen. Principal business address for the filers is 780 Third Avenue, 30th Floor, New York, NY 10017.